Early evaluation of treatment response and prediction of disease evolution are key issues in
the management of people with multiple sclerosis (MS). In the past 20 years, MRI has …

Dimethyl fumarate (DMF) is an effective treatment option for relapsing–remitting multiple
sclerosis (MS), but its therapeutic mechanism of action has not been fully elucidated. A …

Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system
characterized by focal or diffuse inflammation, demyelination, axonal loss and …

Despite important advances in the treatment of multiple sclerosis (MS) over recent years, the
introduction of several disease-modifying therapies (DMTs), the burden of progressive …

Background Progressive disability in multiple sclerosis occurs because CNS axons
degenerate as a late consequence of demyelination. In animals, retinoic acid receptor RXR …

Increasing numbers of drugs are being developed for the treatment of multiple sclerosis
(MS). Measurement of relevant outcomes is key for assessing the efficacy of new drugs in …

Brain imaging is increasingly used to support clinicians in diagnosing multiple sclerosis
(MS) and monitoring its progression. However, the role of magnetic resonance imaging …

The transcription factor NF-E2 p45-related factor 2 (NRF2; encoded by NFE2L2) plays a
critical role in the maintenance of cellular redox and metabolic homeostasis, as well as the …

Multiple sclerosis (MS) is an autoimmune, chronic, progressive disease leading to a
combination of inflammation, demyelination, and neurodegeneration throughout the central …

Dimethyl fumarate (Tecfidera®) is approved for the treatment of relapsing forms of multiple
sclerosis (MS). Based on evidence from the clinical trial and real-world settings, dimethyl …